Apellis Pharmaceuticals Operating Margin vs. Net Income
| APLS Stock | USD 20.54 0.21 1.03% |
Apellis Pharmaceuticals Operating Profit Margin |
|
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.98 | 0.8493 |
|
|
For Apellis Pharmaceuticals profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Apellis Pharmaceuticals to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Apellis Pharmaceuticals utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Apellis Pharmaceuticals's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Apellis Pharmaceuticals over time as well as its relative position and ranking within its peers.
Apellis Pharmaceuticals' Revenue Breakdown by Earning Segment
Check out Trending Equities.
Apellis Pharmaceuticals Revenue Breakdown by Earning Segment
By analyzing Apellis Pharmaceuticals' earnings estimates, investors can diagnose different trends across Apellis Pharmaceuticals' analyst sentiment over time as well as compare current estimates against different timeframes.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Apellis Pharmaceuticals. If investors know Apellis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Apellis Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 0.36 | Revenue Per Share | Quarterly Revenue Growth 1.33 | Return On Assets | Return On Equity |
The market value of Apellis Pharmaceuticals is measured differently than its book value, which is the value of Apellis that is recorded on the company's balance sheet. Investors also form their own opinion of Apellis Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Apellis Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Apellis Pharmaceuticals' market value can be influenced by many factors that don't directly affect Apellis Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Apellis Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Apellis Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Apellis Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Apellis Pharmaceuticals Net Income vs. Operating Margin Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Apellis Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Apellis Pharmaceuticals value to that of its competitors to determine the firm's financial worth. Apellis Pharmaceuticals is rated second in operating margin category among its peers. It is rated below average in net income category among its peers . At this time, Apellis Pharmaceuticals' Operating Profit Margin is comparatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Apellis Pharmaceuticals by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Apellis Net Income vs. Operating Margin
Operating Margin shows how much operating income a company makes on each dollar of sales. It is one of the profitability indicators which helps analysts to understand whether the firm is successful or not making money from everyday operations.
Apellis Pharmaceuticals |
| = | 0.49 % |
A good Operating Margin is required for a company to be able to pay for its fixed costs or payout its debt, which implies that the higher the margin, the better. This ratio is most effective in evaluating the earning potential of a company over time when comparing it against a firm's competitors.
Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Apellis Pharmaceuticals |
| = | (197.88 M) |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
Apellis Net Income Comparison
Apellis Pharmaceuticals is currently under evaluation in net income category among its peers.
Apellis Pharmaceuticals Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Apellis Pharmaceuticals, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Apellis Pharmaceuticals will eventually generate negative long term returns. The profitability progress is the general direction of Apellis Pharmaceuticals' change in net profit over the period of time. It can combine multiple indicators of Apellis Pharmaceuticals, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | -3 M | -2.8 M | |
| Operating Income | -148.5 M | -155.9 M | |
| Income Before Tax | -177 M | -185.9 M | |
| Total Other Income Expense Net | -28.6 M | -30 M | |
| Net Loss | -178.1 M | -187 M | |
| Net Loss | -178.1 M | -187 M | |
| Net Loss | -587 M | -557.6 M | |
| Income Tax Expense | 1.3 M | 1.4 M | |
| Net Interest Income | -24.9 M | -23.6 M | |
| Interest Income | 14.7 M | 7.6 M | |
| Change To Netincome | 174.9 M | 183.7 M | |
| Net Loss | (1.84) | (1.93) | |
| Income Quality | 0.51 | 0.86 | |
| Net Income Per E B T | 0.91 | 0.80 |
Apellis Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Apellis Pharmaceuticals. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Apellis Pharmaceuticals position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Apellis Pharmaceuticals' important profitability drivers and their relationship over time.
Apellis Pharmaceuticals Earnings Estimation Breakdown
The calculation of Apellis Pharmaceuticals' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Apellis Pharmaceuticals is estimated to be 0.06615 with the future projection ranging from a low of 0.01 to a high of 0.12. Please be aware that this consensus of annual earnings estimates for Apellis Pharmaceuticals is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
0.01 Lowest | Expected EPS | 0.12 Highest |
Apellis Pharmaceuticals Earnings Projection Consensus
Suppose the current estimates of Apellis Pharmaceuticals' value are higher than the current market price of the Apellis Pharmaceuticals stock. In this case, investors may conclude that Apellis Pharmaceuticals is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Apellis Pharmaceuticals' stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of December 2025 | Current EPS (TTM) | |
| 21 | 79.25% | 1.67 | 0.06615 | 0.36 |
Apellis Pharmaceuticals Earnings per Share Projection vs Actual
Actual Earning per Share of Apellis Pharmaceuticals refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Apellis Pharmaceuticals predict the company's earnings will be in the future. The higher the earnings per share of Apellis Pharmaceuticals, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.Apellis Pharmaceuticals Estimated Months Earnings per Share
For an investor who is primarily interested in generating an income out of investing in entities such as Apellis Pharmaceuticals, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Apellis Pharmaceuticals should always be considered in relation to other companies to make a more educated investment decision.Apellis Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises can significantly impact Apellis Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2025-11-10 | 2025-09-30 | 1.6 | 1.67 | 0.07 | 4 | ||
2025-07-31 | 2025-06-30 | -0.48 | -0.33 | 0.15 | 31 | ||
2025-05-05 | 2025-03-31 | -0.54 | -0.74 | -0.2 | 37 | ||
2025-02-25 | 2024-12-31 | -0.4019 | -0.29 | 0.1119 | 27 | ||
2024-11-05 | 2024-09-30 | -0.3 | -0.4624 | -0.1624 | 54 | ||
2024-08-01 | 2024-06-30 | -0.32 | -0.28 | 0.04 | 12 | ||
2024-05-07 | 2024-03-31 | -0.47 | -0.42 | 0.05 | 10 | ||
2024-02-27 | 2023-12-31 | -0.69 | -0.73 | -0.04 | 5 | ||
2023-11-01 | 2023-09-30 | -0.86 | -1.17 | -0.31 | 36 | ||
2023-07-31 | 2023-06-30 | -1.32 | -1.02 | 0.3 | 22 | ||
2023-05-04 | 2023-03-31 | -1.46 | -1.56 | -0.1 | 6 | ||
2023-02-21 | 2022-12-31 | -1.57 | -1.5 | 0.07 | 4 | ||
2022-11-07 | 2022-09-30 | -1.45 | -1.75 | -0.3 | 20 | ||
2022-08-08 | 2022-06-30 | -1.36 | -1.46 | -0.1 | 7 | ||
2022-05-04 | 2022-03-31 | -1.32 | -1.42 | -0.1 | 7 | ||
2022-02-28 | 2021-12-31 | -1.54 | -1.61 | -0.07 | 4 | ||
2021-11-08 | 2021-09-30 | -1.7 | -2.28 | -0.58 | 34 | ||
2021-08-09 | 2021-06-30 | -1.69 | -2.72 | -1.03 | 60 | ||
2021-04-28 | 2021-03-31 | -1.62 | -2.32 | -0.7 | 43 | ||
2021-02-25 | 2020-12-31 | -0.75 | 0.93 | 1.68 | 224 | ||
2020-11-02 | 2020-09-30 | -1.58 | -1.79 | -0.21 | 13 | ||
2020-07-30 | 2020-06-30 | -1.34 | -1.57 | -0.23 | 17 | ||
2020-04-29 | 2020-03-31 | -1.38 | -2.29 | -0.91 | 65 | ||
2020-02-27 | 2019-12-31 | -1.14 | -1.77 | -0.63 | 55 | ||
2019-11-05 | 2019-09-30 | -1.01 | -1.1 | -0.09 | 8 | ||
2019-07-31 | 2019-06-30 | -0.77 | -1.12 | -0.35 | 45 | ||
2019-05-07 | 2019-03-31 | -0.67 | -0.87 | -0.2 | 29 | ||
2019-02-26 | 2018-12-31 | -0.7 | -0.65 | 0.05 | 7 | ||
2018-11-13 | 2018-09-30 | -0.69 | -0.64 | 0.05 | 7 | ||
2018-07-31 | 2018-06-30 | -0.47 | -0.61 | -0.14 | 29 | ||
2018-04-30 | 2018-03-31 | -0.33 | -0.43 | -0.1 | 30 | ||
2018-03-19 | 2017-12-31 | -0.48 | -0.6 | -0.12 | 25 | ||
2017-12-20 | 2017-09-30 | -0.87 | -1.37 | -0.5 | 57 | ||
2017-08-30 | 2017-06-30 | 0 | -1.26 | -1.26 | 0 | ||
2017-05-04 | 2017-03-31 | 0 | -1.07 | -1.07 | 0 |
Use Apellis Pharmaceuticals in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Apellis Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Apellis Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Apellis Pharmaceuticals Pair Trading
Apellis Pharmaceuticals Pair Trading Analysis
The ability to find closely correlated positions to Apellis Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Apellis Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Apellis Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Apellis Pharmaceuticals to buy it.
The correlation of Apellis Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Apellis Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Apellis Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Apellis Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Apellis Pharmaceuticals position
In addition to having Apellis Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Sport Products Thematic Idea Now
Sport Products
Companies manufacturing sporting goods and accessories. The Sport Products theme has 48 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Sport Products Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Apellis Stock Analysis
When running Apellis Pharmaceuticals' price analysis, check to measure Apellis Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Apellis Pharmaceuticals is operating at the current time. Most of Apellis Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Apellis Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Apellis Pharmaceuticals' price. Additionally, you may evaluate how the addition of Apellis Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.